Literature DB >> 23950214

Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later.

Lisa G Aspinwall1, Jennifer M Taber, Samantha L Leaf, Wendy Kohlmann, Sancy A Leachman.   

Abstract

BACKGROUND: A major goal of predictive genetic testing for melanoma is to promote early detection to reduce mortality. This study evaluated the long-term impact of melanoma genetic test reporting and counseling on screening adherence.
METHODS: This study assessed adherence to recommendations for annual total body skin examinations (TBSE) and monthly skin self-examinations (SSE) among 37 members of Utah CDKN2A/p16 kindreds (10 unaffected carriers, 11 affected carriers, and 16 unaffected noncarriers; response rate = 64.9% of eligible participants).
RESULTS: Two years following test reporting, adherence to annual TBSE among unaffected carriers increased from 40% to 70%. However, unaffected noncarriers' adherence decreased from 56% to 13%. Affected carriers reported TBSEs at both assessments (91% and 82%, respectively). Monthly SSE frequency remained highly variable in all patient groups: at 2 years, 29.7% reported monthly SSEs, 27.0% reported more frequent self-examinations, and 43.2% reported underscreening. However, SSE quality improved significantly: participants checked more body sites at 2 years than at baseline, especially feet, shoulders, legs, and genitals. Perceived logistic barriers to TBSEs (e.g., expensive, inconvenient) and SSEs (hard to remember, time-consuming) predicted lower adherence.
CONCLUSIONS: Unaffected carriers reported increased TBSE adherence and thoroughness of SSEs 2 years following melanoma genetic test reporting, suggesting clinical benefit in this modest sample. Unaffected noncarriers reported comparable gains in SSE thoroughness, but decreased TBSEs. IMPACT: Melanoma genetic counseling and test reporting may improve adherence among unaffected carrier members of p16 families. Further interventions to reduce logistic barriers and to promote continued screening adherence among unaffected noncarrier family members may be needed.

Entities:  

Mesh:

Year:  2013        PMID: 23950214      PMCID: PMC3837428          DOI: 10.1158/1055-9965.EPI-13-0422

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  19 in total

1.  A vision for the future of genomics research.

Authors:  Francis S Collins; Eric D Green; Alan E Guttmacher; Mark S Guyer
Journal:  Nature       Date:  2003-04-14       Impact factor: 49.962

2.  Population-based analysis of prognostic factors and survival in familial melanoma.

Authors:  Scott R Florell; Kenneth M Boucher; Gilda Garibotti; John Astle; Richard Kerber; Geraldine Mineau; Charles Wiggins; R Dirk Noyes; Alexander Tsodikov; Lisa A Cannon-Albright; John J Zone; Wolfram E Samlowski; Sancy A Leachman
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

Review 3.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

Authors:  C M Balch; A C Buzaid; S J Soong; M B Atkins; N Cascinelli; D G Coit; I D Fleming; J E Gershenwald; A Houghton; J M Kirkwood; K M McMasters; M F Mihm; D L Morton; D S Reintgen; M I Ross; A Sober; J A Thompson; J F Thompson
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

Review 4.  Is there a role for genetic testing in patients with melanoma?

Authors:  Richard F Kefford; Graham J Mann
Journal:  Curr Opin Oncol       Date:  2003-03       Impact factor: 3.645

5.  Geographical variation in the penetrance of CDKN2A mutations for melanoma.

Authors:  D Timothy Bishop; Florence Demenais; Alisa M Goldstein; Wilma Bergman; Julia Newton Bishop; Brigitte Bressac-de Paillerets; Agnès Chompret; Paola Ghiorzo; Nelleke Gruis; Johan Hansson; Mark Harland; Nicholas Hayward; Elizabeth A Holland; Graham J Mann; Michela Mantelli; Derek Nancarrow; Anton Platz; Margaret A Tucker
Journal:  J Natl Cancer Inst       Date:  2002-06-19       Impact factor: 13.506

6.  Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22.

Authors:  L A Cannon-Albright; D E Goldgar; L J Meyer; C M Lewis; D E Anderson; J W Fountain; M E Hegi; R W Wiseman; E M Petty; A E Bale
Journal:  Science       Date:  1992-11-13       Impact factor: 47.728

Review 7.  Clinical germline genetic testing for melanoma.

Authors:  Christopher B Hansen; Lisa M Wadge; Katrina Lowstuter; Kenneth Boucher; Sancy A Leachman
Journal:  Lancet Oncol       Date:  2004-05       Impact factor: 41.316

8.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.

Authors:  A Kamb; D Shattuck-Eidens; R Eeles; Q Liu; N A Gruis; W Ding; C Hussey; T Tran; Y Miki; J Weaver-Feldhaus
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

9.  CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families.

Authors:  Lisa G Aspinwall; Samantha L Leaf; Erin R Dola; Wendy Kohlmann; Sancy A Leachman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-06       Impact factor: 4.254

Review 10.  The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?

Authors:  Muin J Khoury; Marta Gwinn; Paula W Yoon; Nicole Dowling; Cynthia A Moore; Linda Bradley
Journal:  Genet Med       Date:  2007-10       Impact factor: 8.822

View more
  23 in total

Review 1.  Clinical applications of melanoma genetics.

Authors:  Michele Gabree; Devanshi Patel; Linda Rodgers
Journal:  Curr Treat Options Oncol       Date:  2014-06

2.  Genetic test reporting enhances understanding of risk information and acceptance of prevention recommendations compared to family history-based counseling alone.

Authors:  Jennifer M Taber; Lisa G Aspinwall; Tammy K Stump; Wendy Kohlmann; Marjan Champine; Sancy A Leachman
Journal:  J Behav Med       Date:  2015-07-16

Review 3.  Barriers to risk-understanding and risk-reduction behaviors among individuals with a family history of melanoma.

Authors:  Laura Fitzpatrick; Jennifer L Hay
Journal:  Melanoma Manag       Date:  2014-12-04

Review 4.  Update in genetic susceptibility in melanoma.

Authors:  Miriam Potrony; Celia Badenas; Paula Aguilera; Joan Anton Puig-Butille; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  Ann Transl Med       Date:  2015-09

5.  Impact of melanoma genetic test reporting on perceived control over melanoma prevention.

Authors:  Lisa G Aspinwall; Tammy K Stump; Jennifer M Taber; Wendy Kohlmann; Samantha L Leaf; Sancy A Leachman
Journal:  J Behav Med       Date:  2015-03-31

6.  Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

Authors:  Paolo A Ascierto; Antonio M Grimaldi; Ana Carrizosa Anderson; Carlo Bifulco; Alistair Cochran; Claus Garbe; Alexander M Eggermont; Mark Faries; Soldano Ferrone; Jeffrey E Gershenwald; Thomas F Gajewski; Ruth Halaban; F Stephen Hodi; Richard Kefford; John M Kirkwood; James Larkin; Sancy Leachman; Michele Maio; Richard Marais; Giuseppe Masucci; Ignacio Melero; Giuseppe Palmieri; Igor Puzanov; Antoni Ribas; Yvonne Saenger; Bastian Schilling; Barbara Seliger; David Stroncek; Ryan Sullivan; Alessandro Testori; Ena Wang; Gennaro Ciliberto; Nicola Mozzillo; Francesco M Marincola; Magdalena Thurin
Journal:  J Transl Med       Date:  2014-10-28       Impact factor: 5.531

7.  An experiment assessing effects of personalized feedback about genetic susceptibility to obesity on attitudes towards diet and exercise.

Authors:  Woo-Kyoung Ahn; Matthew S Lebowitz
Journal:  Appetite       Date:  2017-08-31       Impact factor: 3.868

8.  Blue Genes? Understanding and Mitigating Negative Consequences of Personalized Information about Genetic Risk for Depression.

Authors:  Matthew S Lebowitz; Woo-Kyoung Ahn
Journal:  J Genet Couns       Date:  2017-08-07       Impact factor: 2.537

9.  Perceived risk following melanoma genetic testing: a 2-year prospective study distinguishing subjective estimates from recall.

Authors:  Lisa G Aspinwall; Jennifer M Taber; Wendy Kohlmann; Samantha L Leaf; Sancy A Leachman
Journal:  J Genet Couns       Date:  2013-12-10       Impact factor: 2.537

Review 10.  A systematic review of interventions to improve adherence to melanoma preventive behaviors for individuals at elevated risk.

Authors:  Yelena P Wu; Lisa G Aspinwall; Bridgid M Conn; Tammy Stump; Bridget Grahmann; Sancy A Leachman
Journal:  Prev Med       Date:  2016-04-16       Impact factor: 4.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.